Earnings Outlook For Novo Nordisk

Novo Nordisk (NYSE:NVO) is set to give its latest quarterly earnings report on Thursday, 2023-08-10. Here’s what investors…

Novo Nordisk (NYSE:NVO) is set to give its latest quarterly earnings report on Thursday, 2023-08-10. Here’s what investors need to know before the announcement.

Analysts estimate that Novo Nordisk will report an earnings per share (EPS) of $1.28.

Novo Nordisk bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company missed EPS by $0.01, which was followed by a 1.75% increase in the share price the next day.

Here’s a look at Novo Nordisk’s past performance and the resulting price change:

Quarter Q1 2023 Q4 2022 Q3 2022 Q2 2022
EPS Estimate 1.28 0.85 0.83 0.82
EPS Actual 1.27 0.81 0.86 0.84
Price Change % 1.75% -4.85% 0.62% 4.82%

eps graph

Stock Performance

Shares of Novo Nordisk were trading at $189.17 as of August 08. Over the last 52-week period, shares are up 73.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Novo Nordisk visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Orthopedic Devices Maker Treace Medical Concepts’ Gloomy Forecast Cast Concerns Over Long-Term Viability

Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to expanded surgeon base and product mix shift. FY24 sales guidance adjusted to $201M-$211M. Analysts downgrade, citing competitive challenges.

TMCI

Read More

$21.8M Revenue For NASDAQ-Listed Psychedelics Ancillary Company Societal CDMO’s Q2 2023

Societal CDMO Inc. (NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for small molecule therapeutics, reported financial results for the three and six months ended June 30, 2023.

SCTL